40251 - 8th Tumor Models San Francisco Summit 2024

Conference themes
Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, 2023 has set an exciting precedent for the upcoming year.

Professional congress organizer (PCO)
Hanson Wade

Notes
Brochure: https://go.evvnt.com/1948808-0?pid=4832

Speakers: Alba Gonzalez-Junca - Associate Director - Arsenal Biosciences, Aldo Pourchet - Chief Executive Officer and Co-Founder - Omios Biologics, and more.

https://go.evvnt.com/1948808-2?pid=4832

Ms. Anita Keleman